Cystic Fibrosis is a disease characterized by insufficient production of CFTR (or enough production but with an abnormal molecular structure) CTFR is an acronym for cystic fibrosis transmembrane regulator, a protein that plays a major role in our respiratory system. CFTR protein exists on pulmonary cell surfaces and assists in pulmonary functions, regulating the exchange of sodium, H2O and chloride ions throughout the cell membrane. Periodic or chronic sinusitis and lung infections are common in cystic fibrosis.
“Changing diagnostic criteria and methods, as well as improvements in clinical outcome, have influenced the epidemiology of cystic fibrosis. Estimates of disease incidence are around 1 in 3,000 live births in persons of northern European descent, with Ireland having the highest incidence at 1 in 1,400 live births. Incidence varies according to race and ethnicity; only 1 in 4,000 to 10,000 Latin Americans and 1 in 15,000 to 20,000 African Americans have cystic fibrosis, with even lower incidence rates in people of Asian background. These estimates are based on information from western countries — epidemiological data are missing for large regions of the world, including the Middle East, Asia and Africa. Importantly, some small populations in Eastern Europe have very high incidence rates, specifically Albania, where the incidence was noted to be 1 in 555. This high incidence is also reflected in data noting very high incidence in Albanian immigrants to northern Italy. The introduction of prenatal genetic screening in western countries seems to correlate with decreasing incidence in some countries. Although the incidence is decreasing, data from registries suggest that the prevalence is increasing because of improvements in survival.”1
“Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities. The genetic basis for CF (Cystic fibrosis) is a well-characterized, severe monogenic recessive disorder, found predominantly in Caucasian populations of European ancestry that arises from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. While the gene defect results in a myriad of medical problems for the patient, the most meddlesome clinical feature, chronic pulmonary infection with Pseudomonas aeruginosa, allows the basic pathologic process in CF (Cystic fibrosis) to be designated an infectious disease. Ultimately, 80 to 95% of patients with CF (Cystic fibrosis) succumb to respiratory failure brought on by chronic bacterial infection and concomitant airway inflammation.”2
Cystic fibrosis transmits genetically. Genes such as the G551D and the Delta F508 can suffer from mutations, causing cystic fibrosis in two separate ways:
G551D mutations cause the ‘door-jamming mutation’. This faulty mechanism results from the closing of the CFTR protein channel becoming and, therefore, not allowing the proper ions to flow in and out of cells.
Delta F508 mutations cause the CFTR protein to synthesize within the cell but are unable to reach the cell membrane, where it should perform its function.
“The presence of two mutant genes (g) is needed for CF (Cystic Fibrosis) to appear. Each parent carries one defective gene (g) and one normal gene (G). The single normal gene is sufficient for the normal function of the mucous glands, and the parents are therefore CF (Cystic Fibrosis)-free. Each child has a 25 percent risk of inheriting two defective genes and getting CF (Cystic Fibrosis), a 25 percent chance of inheriting two normal genes, and a 50 percent chance of being an unaffected carrier like the parents.”4
The absence or structural inadequacy of CFTR causes normal fluids in the pulmonary air passages, ducts in the pancreas, reproductive system and gastrointestinal tract, to become thicker and mucus-like, instead of normal thin and watery. The production of this thick mucus causes some of the above-mentioned areas to obstruct, increasing the frequency of infections and reducing those organs’ functionality.
Cystic Fibrosis is Systemic
Cystic fibrosis is not limited to the lungs. Instead, it affects us at several systemic levels:
“The organs in which clinical abnormalities have been documented most in CF (Cystic Fibrosis) are the airways, pancreas, and sweat glands. Basic physiological defects predispose the airways to chronic, recurrent infections with associated tissue inflammation that result in progressive deterioration of pulmonary function due to endobronchitis, inspissations, bronchiectasis, and parenchymal destruction. Unfortunately, the link between the chronic respiratory infections uniquely characterized by a mucoid form of Pseudomonas aeruginosa and the abnormal physiological phenomena is not known. Therapy is usually focused on mechanical assistance in clearing the airways of sputum and intermittent administration of antibiotics to suppress pulmonary infection. The loss of parenchymal tissue leads to respiratory failure, which may be complicated by pulmonary hypertension and cor pulmonale. More than 90% of the mortality in cystic fibrosis is due to pulmonary complications.”5
A lack of CFTR causes lungs to produce thick mucus instead of a watery film. This heightened mucus-like environment induces chances of infection and the mechanical disadvantage of the congestion of air passages. Eventually, this chronic obstruction or congestion damages pulmonary tissue.
“Soon after birth, initial infection with bacterial pathogens commences and is associated with an intense neutrophilic response localized to the peribronchial and endobronchial spaces. Early airway infection and inflammation in CF (Cystic Fibrosis) can have regional heterogeneity that complicates understanding the causal and temporal relationship between initial infection and airway inflammatory response. Several studies in toddlers and older children with CF (Cystic Fibrosis) have shown a robust inflammatory response in the airways in both bacterial culture–positive and culture-negative patients; some studies show a greater inflammatory response in those patients with at least 5 x 104 cfu/ml of bacteria in their bronchoalveolar lavage (BAL) fluid. At this point, pathologic changes become more evident with mucopurulent plugging of small and medium size bronchioles. In older individuals with CF (Cystic Fibrosis), persistent neutrophils dominate airway inflammation with elevated interleukin (IL)-8 and neutrophil elastase. Airways become dilated and bronchiectatic, secondary to proteolysis and chondrolysis of airway support tissue. In later stages, lung parenchyma becomes affected by atelectasis, pneumonia, and encroachment by enlarging airways. Many secondary consequences of bronchiectasis ensue, including hypertrophy of bronchial circulation and formation of bronchial cysts. A later and less common consequence is pulmonary hypertension.”6
The pancreas drains its normal content into the intestinal system via several ducts. If these ducts block or clog, the body will not receive the necessary hormones such as insulin, causing cystic fibrosis-induced diabetes. This congestion also causes the pancreatic tissue to scar, affecting the patient long-term.
“As with the lung, the pancreas also shows progressive deterioration with age. Again, the ducts of the pancreas appear to obstruct with inspissation. Luminal obstruction and dilation of the secretory acini and ducts seem to be followed by atrophy and degeneration of the exocrine parenchyma. The endocrine pancreas appears to survive this destruction remarkably well, although the incidence of glucose intolerance increases with age. In general, pancreatic insufficiency is manageable clinically with supplemental pancreatic enzymes that usually suffice to maintain nutrition.”8
Like the pancreas, the liver uses ducts to drain the necessary content that our body requires. Since these ducts block or clog, cystic fibrosis may cause hepatic cirrhosis.
Mucus-like congestion may cause infertility in both men and women.
Due to blockages or congestion, performing surgery may relieve the digestive system.
“It is the consensus of the panel that the diagnosis of CF (Cystic Fibrosis) should be based on the presence of one or more characteristic phenotypic features (Table II), a history of CF (Cystic Fibrosis) in a sibling, or a positive newborn screening test result plus laboratory evidence of a CFTR (cystic fibrosis transmembrane conductance regulator) abnormality as documented by elevated sweat chloride concentration, or identification of mutations in each CFTR (cystic fibrosis transmembrane conductance regulator) gene known to cause CF (Cystic Fibrosis) or in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium.”9
Thanks to advances in medicine and the pursuit of knowledge in the science world, life expectancy has improved. 60 years ago, it was difficult for children with cystic fibrosis to safely go through their youths. In contrast, today’s persons with cystic fibrosis can expect to live at least 40 years with proper management and treatment. The most affected ethnic group is of Caucasian descent but it can affect people of all races.
Early diagnosis of cystic fibrosis
“Newborn screening for cystic fibrosis has been controversial because of its cost, the creation of anxiety around the procedure in seemingly healthy infants and the lack of established pulmonary treatments for infants. The cost of treatment has been shown to be reduced in patients who have been diagnosed through newborn screening compared with those who have had later diagnoses. A randomized controlled trial has clearly shown the efficacy of screening and has provided evidence of nutritional — but not respiratory — benefits. However, a factor in the unexpectedly poor respiratory outcomes in that study might have been a failure to apply modern infection control precautions in one of the participating centers. Much evidence shows benefits when comparing outcomes before and after the introduction of screening. For example, The London Cystic Fibrosis Collaboration showed that infants diagnosed later (in the first 2 years of life) had airway obstruction at presentation, even if they had had no respiratory symptoms or signs, and this never recovered despite specialist treatment. By comparison, the outcomes in babies diagnosed by screening were much more favorable. Another benefit of newborn screening is that parents have the opportunity to make informed choices about antenatal diagnosis in future pregnancies.”11
Lung transplantation is a real possibility?
“Lung transplantation is an established treatment for patients with end-stage pulmonary disease. The outcomes for patients undergoing transplantation for cystic fibrosis have rapidly improved and median survival now approaches or even exceeds 10 years in many treatment centers. Timely referral and close communication between the cystic fibrosis and transplant centers are required to provide sufficient time for assessment of suitability (of the donor and of the recipient), to determine whether indications are met and to establish that there are no foreseeable contraindications. Donor allocation programs vary globally but aim to prioritize those waiting for transplants who have the most limited pre-transplant survival. Adjunctive therapies, including noninvasive ventilation, can function as a bridge to transplantation. The most common cause of graft failure following lung transplantation is bronchiolitis obliterans, which is thought to be a form of chronic allograft rejection.”12
Although cystic fibrosis is a serious condition that requires constant care, treatments have improved considerably over time. Patients with cystic fibrosis have an increased life expectancy and improved quality of life.
(1, 11, 12) Cystic fibrosis. Ratjen, F., Bell, S.C., Rowe, S.M., Goss, C.H., Quittner, A.L. & Bush, A. Nature Reviews. 2015. https://www.researchgate.net/publication/277350830_Cystic_fibrosis
(2) Lung Infections Associated with Cystic. Lyczak, J.B., Cannon, C.L. & Pier, G.B. Clinical Microbiology Reviews. 2002. https://cmr.asm.org/content/15/2/194.full
(3, 4) Cystic Fibrosis. National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health. 1995. https://www.cdc.gov/scienceambassador/documents/cystic-fibrosis-fact-sheet.pdf
(5, 8) Cystic fibrosis: a disease in electrolyte transport. Quinton, P.M. The FASEB Journal. 1990. https://pdfs.semanticscholar.org/dcbf/a0480e17cc46d51a9b182b041ead4dd935b1.pdf
(6, 7) Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Gibson, R.L., Burns, J.L., & Ramsey, B.W. https://www.atsjournals.org/doi/full/10.1164/rccm.200304-505SO
(9, 10) The diagnosis of cystic fibrosis: A consensus. Rosenstein, B.J. & Cutting, G.R. The Journal of Pediatrics. 1998. https://www.sifc.it/sites/default/files/ScreeningTestSudore_Rosenstein_Diagnosi_di_FC_Consensus_statement_1998.pdf